PuraMed BioScience Inc. engages in the research, development and marketing of non-prescription medicines and healthcare products. Its leading product is LipiGesic M, which provides acute relief from migraine headaches. The company also has plans to launch LipiGesic PM, which provides a remedy for insomnia and other sleep disorders as well as LipiGesic H for common tension headaches.

The company announced today that it has entered into an agreement with Media4Equity and its parent company, NewsUSA, for a multimedia marketing campaign over the next year. Media4Equity uses its media and marketing clout and contacts to help strong emerging growth companies grow faster. It will put its extensive staff, resources and 25 years of media syndication experience behind this launch. The company has long-standing relationships with over 16,000 media outlets.

The multimedia campaign will be conducted through newspaper, radio, internet and social media. The equivalent ad value for the number of guaranteed placements equals approximately $2 million, ensuring that the campaign will raise awareness of PuraMed and LipiGesic M on a national basis through extensive coverage. PuraMed plans to launch its LipiGesic M on a retail basis in the third quarter of 2010.

Media4Equity will be paid monthly at a rate of $20,000. It will be at the discretion of PuraMed BioScience whether to pay them in cash or stock. This arrangement provides the company flexibility in payment options for this marketing campaign which PuraMed hopes will greatly raise awareness of the company and its products. For more information on PuraMed BioScience, please visit the company’s website at www.PuraMedBioScience.com and for more information on LipiGesic products, please visit www.lipigesic.com.